Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. [electronic resource]
Producer: 20100526Description: 181-93 p. digitalISSN:- 1754-8411
- AMP-Activated Protein Kinases
- Animals
- Cell Line, Tumor
- Cloning, Molecular
- Cornified Envelope Proline-Rich Proteins -- genetics
- Disease Models, Animal
- Drug Screening Assays, Antitumor
- Endometrial Neoplasms -- drug therapy
- Endometrium -- drug effects
- Enzyme Activation -- drug effects
- Epithelium -- drug effects
- Female
- Integrases -- metabolism
- Intracellular Signaling Peptides and Proteins -- antagonists & inhibitors
- Mice
- Mice, Transgenic
- Neoplasm Invasiveness
- Organ Specificity -- drug effects
- Penetrance
- Protein Kinase Inhibitors -- pharmacology
- Protein Serine-Threonine Kinases -- antagonists & inhibitors
- Response Elements -- genetics
- Sirolimus -- pharmacology
- TOR Serine-Threonine Kinases
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.